Vontobel Holding Ltd. Buys 4,637 Shares of Amgen Inc. $AMGN

Vontobel Holding Ltd. boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 3.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 155,115 shares of the medical research company’s stock after buying an additional 4,637 shares during the quarter. Vontobel Holding Ltd.’s holdings in Amgen were worth $56,170,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. High Note Wealth LLC raised its position in shares of Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. boosted its position in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares in the last quarter. Verus Capital Partners LLC boosted its position in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares in the last quarter. Destination Wealth Management grew its stake in Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after purchasing an additional 29 shares during the period. Finally, Breakwater Capital Group grew its stake in Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after purchasing an additional 29 shares during the period. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on AMGN shares. Truist Financial raised their price objective on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Bank of America increased their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Guggenheim lifted their price target on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Mizuho lifted their price target on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $372.39.

Amgen Stock Down 0.6%

Shares of NASDAQ:AMGN opened at $415.21 on Friday. The stock has a fifty day simple moving average of $370.57 and a two-hundred day simple moving average of $358.93. The stock has a market capitalization of $224.47 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 3.88 and a beta of 0.41. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $421.79. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the company posted $6.02 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.